Alfimeprase
How Alfimeprase Works |
Potential Therapeutic Applications
Clinical Trials |
Commercialization Rights |
Scientific Publications and Presentations
Scientific Publications
Toombs C, Deitcher S.
Nonclinical and clinical characterization of a novel acting thrombolytic: alfimeprase
Toxin Reviews (formerly Journal of Toxicology: Toxin Reviews), Volume 25, Number 3/July-September 2006: 375-88.
Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher S.
Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices
J Clin Oncol. 2006 Jul 1;24(19):3056-60.
Hong TT, Huang J, Lucchesi BR.
Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase
Am J Physiol Heart Circ Physiol 2006 March;
290(3):H959-H967.
NOTE: Full text of the article is accessible through the link above; please click "Full Text (PDF)" on the right side of the journal abstract site to automatically download the full text of the article.
Ouriel K, Cynamon J, Weaver F, Dardik H, Akers D, Blebea J, Gruneiro L, Toombs C, Wang-Clow F, Mohler, M, Pena L, Wan Ching-Yi, Deitcher S.
A Phase I Trial of Alfimeprase for Peripheral Arterial Thrombosis.
Journal of Vascular and Interventional Radiology
2005 August; 16(8):1075-1083.
Deitcher S, Toombs C.
Non-clinical and clinical characterization of a novel acting thrombolytic: alfimeprase.
Pathophysiol Haemost Thromb. 2005;34(4-5):215-20. Review.
Toombs C.
Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis.
Haemostasis 2001 May; 31(3-6):141-147.
Scientific Presentations
Fred A. Weaver, Bruce A. Perler, Michael D. Levy, James Buchanan, Susan M. Begelman, Anthony J. Comerota
Efficacy and Safety of Alfimeprase in Subjects with Acute Peripheral Arterial Occlusion (PAO): The NAPA Phase 3 Program (PDF)
2008 International Symposium on Endovascular Therapy
January 2008
Stephan Moll, Nashat Gabrail2, Jim Buchanan, Mohammad Hirmand, Michael Levy, Ralph Zitnik
Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices: The SONOMA-2 Study (PDF)
American Society of Hematology 49th Annual Meeting and Exposition
December 2007
Deitcher S, Begelman S, on behalf of the Novel Arterial Perfusion with Alfimeprase (NAPA-1) Investigators
Alfimeprase, a Novel Direct-Acting Fibrinolytic Agent in Acute Peripheral Arterial Occlusion: Report of a Phase 2, Multi-Center, Open-Label, Dose-Defining Study (NAPA-1)
American Heart Association Scientific Sessions November 2006
Deitcher S, Moll S, Kenyon P, Swischuk P, Bertoli L, De Maio J, Homesley H, PeŇa L.
Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters: Interim Results of a Phase 2, Multicenter, Randomized, Double-Blind Study (NuCath).
American Society of Hematology 46th Annual Meeting and Exposition December 2004
Supporting Materials: ASH Phase 2 Catheter Occlusion Presentation
Ouriel, K.
Safety and Activity of Alfimeprase for Catheter-Directed Thrombolysis in Patients with Lower Extremity Acute Peripheral Arterial Occlusion: Report of a Phase 2, Multi-Center, Multi-National, Open-Label, Dose-Escalation Study (NAPA-1)
Transcatheter Cardiovascular Therapeutics September 2004
The attached publications and presentations reflect the actual data and other content prepared by the author(s) and presenter(s) as of the date indicated for each publication or presentation. Nuvelo disclaims any obligation to update the data reflected in these publications and presentations.